Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGB-15025
- Development stage
- Phase 2
- Lead developer
- BeiGene
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
BGB-15025 is a potent and highly selective small molecule inhibitor of hematopoietic progenitor kinase 1 (HPK1), a kinase that acts as a negative regulator of T-cell receptor (TCR) signaling and dendritic cell activation. By inhibiting HPK1, BGB-15025 aims to enhance immune cell activation and antitumor immunity. It is being developed primarily for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC), both as monotherapy and in combination with the anti-PD-1 monoclonal antibody tislelizumab. Preclinical studies have shown preliminary antitumor effects, particularly when used in combination with immunotherapy agents[2][3][4][5][6].
- Other names
- BGB-15025 citrateBGB15025 citrateBGB 15025 citrate
02
Targets
MAP4K1 (Hematopoietic progenitor kinase 1)
Beyond the preview
Go deeper on BGB-15025.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGB-15025.